Acurx Pharmaceuticals Secures New Patent for DNA Polymerase IIIC Inhibitors

Event summary

  • USPTO granted Acurx a new patent (US 12,534,470) for DNA Polymerase IIIC inhibitors, expanding its IP portfolio.
  • Acurx now holds four U.S. patents and additional patents in Israel, Japan, India, and Australia.
  • The patent covers compositions-of-matter, methods of use, and pharmaceutical compositions for the ACX-375C program.
  • Ibezapolstat, Acurx's lead candidate, is Phase 3-ready for treating C. difficile Infection.
  • Preclinical compounds show potential for treating ABSSSI, pneumonia, bacteremia, and anthrax.

The big picture

Acurx's new patent strengthens its position in the antibiotic space, particularly for difficult-to-treat Gram-positive bacterial infections. The company's focus on DNA Polymerase IIIC inhibitors aligns with the growing need for novel antibiotics amid rising resistance. With ibezapolstat poised for Phase 3 trials and a expanding preclinical pipeline, Acurx is positioning itself as a key player in the development of next-generation antibiotics. The strategic significance lies in the potential to address critical unmet needs in infectious disease treatment, including bioterrorism threats like anthrax.

What we're watching

Pipeline Expansion
How Acurx's preclinical compounds will progress through development for multiple indications, including ABSSSI and anthrax.
Regulatory Approval
Whether ibezapolstat will successfully advance through Phase 3 trials and secure FDA approval for C. difficile Infection.
Market Differentiation
The pace at which Acurx can demonstrate the microbiome selectivity of its compounds as a class effect, potentially differentiating its products from competitors like linezolid.